Esther Priel

Revealing the mode of action of DNA topoisomerase I and its inhibitors by atomic force microscopy.

DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.

Implications of the evolution pattern of human T-cell leukemia retroviruses on their pathogenic virulence (Review).

PolyADP-ribosylation is involved in neurotrophic activity.

DNA topoisomerase I in the mouse central nervous system: Age and sex dependence.

A fatal effect of hornet venom on rat-brain cortical neurons.

HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor.

Dose-dependent dual effect of HTLV-1 tax oncoprotein on p53-dependent nucleotide excision repair in human T-cells.

Modification of topoisomerase I activity by glucose and by O-GlcNAcylation of the enzyme protein.

Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.

Glutamate regulates the activity of topoisomerase I in mouse cerebellum.

Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals.

Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.

Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney, liver and pancreas.

Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis.

Telomerase expression in adult and old mouse Purkinje neurons.

Mycoplasma fermentans inhibits the activity of cellular DNA topoisomerase I by activation of PARP1 and alters the efficacy of its anti-cancer inhibitor.

Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.